C3 and primary membranoproliferative glomerulonephritis: Together, these data indicate that pegcetacoplan targets the underlying pathophysiology of C3 dysregulation, reduces disease activity, and is well-tolerated in kidney transplant recipients with recurrent C3G or primary IC-MPGN.